

CURRICULUM VITAE

Elena Crisà , M.D.

Date of birth: January 24, 1984
Place of birth: Torino, Italy
Citizenship: Italian
Contacts: E-mail: elena.crisa@med.uniupo.it

EDUCATION

1997 – 2002 High School at “Liceo classico statale Massimo D’Azeglio”, Torino, Italy
2002 – 2008 School of Medicine, University of Torino, Italy: M.D degree with the highest score (110/110 summa cum laude)
2004 First Certificate in English
2009 Italian Board Examination for M.D.
2009 - June 2014 Post-graduate School of Hematology; University of Torino. Specialization degree with the highest score (70/70 summa cum laude) .
2016- present PHD in Molecular Medicine

PROFESSIONAL RECORDS

2007-2008 Internship in the Department of Haematology, University of Torino, Italy.
2009- August 2013 Specialist training in Haematology, University of Torino, Italy
September 2013 - December 2014 Fellowship in Haematology, King’s College Hospital, London, United Kingdom
January 2015- July 2017 Fellowship in Haematology, University of Torino, Italy
August 2017-present Hematologist at Hematology Division, A.O.U Maggiore della Carità, Novara, Italy
March 2018- present Lecturer of Hematology, Biotechnology school, Università del Piemonte Orientale, Novara
April 2018- present Member of the board of the Italian Foundation on Myelodysplastic syndrome (Fondazione Italiana per lo studio delle Sindromi Mielodisplastiche -FISM)

Clinical practice

Outpatient and inward care of neoplastic and non neoplastic hematological patients, in particular of patients affected by myelodysplastic syndromes, acute myeloid leukemias and myeloproliferative disorders.

Research involvement:

Principal investigator or sub-investigator in national and international clinical trials and observational studies in myelodysplastic syndromes, acute myeloid leukaemia and myeloproliferative neoplasm.

PUBLICATIONS

1. **Crisà E**, Cilloni D, Elli EM, Martinelli V, Giuseppe A, Palumbo GA, Pugliese N, Beggiano E, Frairia C, Cerrano M, Lanzarone G, Marchetti M, Mezzabotta M, Boccadoro M and Ferrero D.
The use of erythropoiesis stimulating agents (ESAs) is safe and effective in the management of anaemia in myelofibrosis patients treated with Ruxolitinib
Br J Haematol, accepted for publication, 2018.
2. Buckstein R, Balleari E, Wells R, Santini V, Sanna A, Salvetti C, **Crisà E**, Allione B, Danise P, Finelli C, Clavio M, Poloni A, Salvi F, Cilloni D, Oliva EN, Musto P, Houston B, Zhu N, Geddes M, Leitch H, Leber B, Sabloff M, Nevill TJ, Yee K, Storrington JM, Francis J, Maurillo L, Latagliata R, Spiriti MAA, Andriani A, Piccioni AL, Fianchi L, Fenu S, Gumenyuk S, Buccisano F.
ITACA: A New Validated International Erythropoietic Stimulating Agent-Response Score that Further Refines the Predictive Power of Previous Scoring Systems.
Am J Hematol. 2017 Jul 4. doi: 10.1002/ajh.24842. [Epub ahead of print]
3. **Crisà E**, Cerrano M, Beggiano E, Benevolo G, Lanzarone G, Manzini PM, Borchiellini A, Riera L, Boccadoro M, Ferrero D.
Can pegylated interferon improve the outcome of polycythemia vera patients?
J Hematol Oncol. 2017 Jan 13;10(1):15. doi: 10.1186/s13045-017-0395-1.
4. Cerrano M, **Crisà E**, Gai V, Boccadoro M, Ferrero D.
Anemia in the elderly: not always what it seems.
Mediterr J Hematol Infect Dis. 2016 Feb 25;8(1):e2016017. doi: 10.4084/MJHID.2016.017. ECollection 2016
5. Ferrero D, Cerrano M, **Crisà E**, Aguzzi C, Gai V, Boccadoro M.

How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.

Br J Haematol. 2016 Feb 23. doi: 10.1111/bjh.13983. [Epub ahead of print]

6. Giaccone L, Audisio E, Bruno B, Maffini E, D'Ardia S, Caracciolo D, Ferrando F, Butera S, Brunello L, Frairia C, Aydin S, Nicolino B, Festuccia M, **Crisà E**, Bruna R, Passera R, Boccadoro M, Vitolo U, Busca A, Falda M, Marmont F.
Role of Chemotherapy and Allografting in the Treatment of Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2016 Feb;16(2):96-103.
7. **Crisà E**, Cerrano M, Gatti T, Giai V, Aguzzi C, Boccadoro M and Ferrero D
The Combination of Fludarabine + Citarabine +Idarubicin (FLAI), Followed by Post-Remission Maintenance, is a Safe and Effective Treatment for Elderly Patients with AML or High Risk MDS
Ann Hematol Oncol. 2015; 2(8): 1056.
8. Breccia M, Luciano L, Latagliata R, Castagnetti F, Ferrero D, Cavazzini F, Trawinska MM, Annunziata M, Stagno F, Tiribelli M, Binotto G, **Crisà E**, Musto P, Gozzini A, Cavalli L, Montefusco E, Iurlo A, Russo S, Cedrone M, Rossi AR, Pregno P, Endri M, Spadea A, Molica M, Giglio G, Celesti F, Sorà F, Storti S, D'Addosio A, Cambrin GR, Isidori A, Sica S, Abruzzese E, Speccha G, Rosti G, Alimena G.
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. Leuk Res. 2014 Oct;38(10):1173-6.
9. Ferrero D.*, **Crisà E***, Marmont F, Audisio E, Frairia C, Giai V, Gatti T, Festuccia M, Bruno B, Riera L, Passera R, Boccadoro M.
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
Ann Hematol. 2014 Aug;93(8):1391-400.
**Dario Ferrero and Elena Crisà equally contributed to the clinical study and to paper preparation.*
10. Cerrano M, **Crisà E**, Pregno P, Aguzzi C, Riccomagno P, Boccadoro M, Ferrero D.
Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients.
Am J Hematol. 2013 Oct;88(10):838-42. Epub 2013 Jul 23.
11. Lobetti-Bodoni C, Ferrero D, Genuardi E, Passera R, Bernocco E, Sia D, Grignani G, **Crisà E**, Monitillo L, Rocci A, Drandi D, Giai V, Zanni M, Boi M, Isaia G, Barbero D, Lunghi M,

- Abruzzese E, Radaelli F, Pini M, Pregno P, Carlo-Stella C, Gaidano G, Boccadoro M, Ladetto M.
Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: Evidence for premature aging of the myeloid compartment.
Mech Ageing Dev. 2012 Jul;133(7):479-88.
12. **Crisà E**, Foli C, Passera R, Darbesio A, Garvey KB, Boccadoro M, Ferrero D. Long-term follow-up of myelodysplastic syndrome patients with moderate/severe anaemia receiving human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3: independent positive impact of erythroid response on survival.
Br J Haematol. 2012 Jul;158(1):99-107
13. Latagliata R, Breccia M, Castagnetti F, Stagno F, Luciano L, Gozzini A, Ulisciani S, Cavazzini F, Annunziata M, Sorà F, Rossi AR, Pregno P, Montefusco E, Abruzzese E, **Crisà E**, Musto P, Tiribelli M, Binotto G, Occhini U, Feo C, Vigneri P, Santini V, Fava C, Rosti G, Alimena G.
Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib.
Leuk Res 2011 Sep;35(9):1164-9.
14. **Crisà E**, Venturino E, Passera R, Prina M, Schinco PC, Borchiellini A, Giai V, Ciocca Vasino MA, Bazzan M, Vaccarino A, Boccadoro M and Ferrero D.
A retrospective study on 226 Polycythemia Vera patients: impact of median haematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs. Ann Hematol. 2010 Jul;89(7):691-9.
15. Ferrero D., **Crisà E**. Problematiche cliniche in ematologia, C.G. Edizioni Medico Scientifiche, Torino 2010

Abstracts

- Oral presentation at EHA 2014 of the abstract entitled: "ISOLATED TOTAL MONOSOMY 7 IS ASSOCIATED WITH BETTER PROGNOSIS IN A LARGE COHORT OF MDS PATIENTS COMPARED WITH OTHER ABNORMALITIES OF CHROMOSOME 7 - A SINGLE INSTITUTE EXPERIENCE"
- Poster presenter at some national and international meetings (ASH, EHA, SIE, SIES), topics: CML, MDS, AML

Original contribution to haematology books

- Ferrero D., Crisà E. Problematiche cliniche in ematologia, C.G. Edizioni Medico Scientifiche, Torino 2010

I authorize to use my personal data according to Decreto legislativo 196, 2003.

Novara, 18/3/2018